Interestingly, data indicate optimal benefit is in part dependent on sequence of therapeutic administration, with cohorts receiving anti-CTLA-4 post vaccination exhibiting higher levels of CD8+ T cells and increased tumor-specific lytic function [160]. The gene discussed is CTLA4; the disease is neoplasm.